Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.

British journal of clinical pharmacology - 1 Feb 2016

Kim Ho-Sook, Lim Younghae, Oh Minkyung, Ghim Jong-Lyul, Kim Eun-Young, Kim Dong-Hyun, Shin Jae-Gook

Abstract excerpt

AIM: The primary objective of the present study was to evaluate the pharmacokinetic and pharmacodynamic interactions between clopidogrel and cilostazol in relation to the CYP2C19 and CYP3A5 genotypes. METHODS: In a randomized, three-way crossover study, 27 healthy subjects were administered clopidogrel (300 mg), cilostazol (100 mg) or clopidogrel + cilostazol orally. Plasma concentrations of clopidogrel,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cross-Over Studies

Share to Drug Synergism

Share to Platelet Aggregation Inhibitors

Share to Tetrazoles

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 26426352
DOI: 10.1111/bcp.12794
PMCID: PMC4833149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.PMID 26426352Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity Read ↗

The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.Semantic proximity Read ↗

Adverse events in cardiovascular disease patients taking clopidogrel: impact of CYP2C19 genotype polymorphismsSemantic proximity Read ↗

The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.Semantic proximity Read ↗

Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.Semantic proximity Read ↗

Cytochrome p-450 polymorphisms and response to clopidogrel.Semantic proximity Read ↗

Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.Semantic proximity Read ↗

Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.Semantic proximity Read ↗

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.Semantic proximity Read ↗

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.Semantic proximity Read ↗

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.